Myriad Genetics Analyst Price Targets - Benzinga

Myriad Genetics Inc

MYGNNASDAQ

Trade with Public

Trade with Public

$4.20

-0.08-1.87%

Últ. Act.: Oct 8, 4:00 PM

$4.20

-0.08-1.87%

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

Myriad Genetics Analyst Price Targets - Benzinga

Myriad Genetics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Myriad Genetics (MYGN).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

4Buy

5Hold

4Sell

Consensus RatingEqual-Weight# Analysts13Avg. Consensus PT$10Upside to Avg. PT+147.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 2, 2026	Craig-Hallum	John Wilkin	PT Raise	Buy	$4→$8
Sep 9, 2026	UBS	Lu Li	PT Cut	Neutral	$6→$4
Sep 1, 2026	Piper Sandler	David Westenberg	Downgrade	Overweight→Underweight	$5→$2
Aug 18, 2026	Stephens & Co.	Mason Carrico	PT Cut	Equal-Weight	$5→$3
Aug 3, 2026	Wells Fargo	Evan Stampler	PT Cut	Equal-Weight	$6→$3
Jul 31, 2026	TD Cowen	Kyle Boucher	PT Cut	Hold	$6→$4
May 6, 2026	TD Cowen	Kyle Boucher	PT Cut	Hold	$7→$6
May 6, 2026	Wells Fargo	Brandon Couillard	PT Cut	Equal-Weight	$6→$6
Feb 24, 2026	UBS	Lu Li	PT Cut	Neutral	$8→$6
Feb 24, 2026	Wells Fargo	Brandon Couillard	PT Cut	Equal-Weight	$7→$6
Nov 11, 2025	Piper Sandler	Dave Weiner	PT Cut	Overweight	$9→$9
Nov 5, 2025	Wells Fargo	Brandon Couillard	PT Raise	Equal-Weight	$6→$7
Nov 4, 2025	TD Cowen	Dan Brennan	PT Raise	Hold	$8→$9
Nov 4, 2025	UBS	Lu Li	PT Raise	Neutral	$6→$8
May 21, 2025	Scotiabank	Sung Ji Nam	Downgrade	Sector Outperform→Sector Perform	$20→$6
May 15, 2025	Piper Sandler	Dave Weiner	PT Cut	Overweight	$13→$9
May 8, 2025	Wells Fargo	Brandon Couillard	Downgrade	Overweight→Equal-Weight	$22→$6
May 7, 2025	Goldman Sachs	Matthew Sykes	PT Cut	Buy	$14→$8
May 7, 2025	UBS	Lu Li	PT Cut	Neutral	$16→$7
May 7, 2025	Raymond James	Andrew Cooper	PT Cut	Outperform	$19→$10

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Craig-Hallum Maintains Buy on Myriad Genetics, Raises Price Target to $8

Craig-Hallum analyst John Wilkin maintains Myriad Genetics (NASDAQ:MYGN) with a Buy and raises the price target from $4 to $8.

Benzinga Newsdesk

PRO
UBS Maintains Neutral on Myriad Genetics, Lowers Price Target to $3.6

UBS analyst Lu Li maintains Myriad Genetics (NASDAQ:MYGN) with a Neutral and lowers the price target from $6 to $3.6.

Benzinga Newsdesk

PRO
Stephens & Co. Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3

Stephens & Co. analyst Mason Carrico maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $5 to $3.

Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3

Wells Fargo analyst Evan Stampler maintains Myriad Genetics (NASDAQ:MYGN) with a Equal-Weight and lowers the price target from $5.5 to $3.

Benzinga Newsdesk

PRO
TD Cowen Maintains Hold on Myriad Genetics, Lowers Price Target to $4

TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the price target from $6 to $4.

Benzinga Newsdesk

PRO
TD Cowen Maintains Hold on Myriad Genetics, Lowers Price Target to $6

TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the price target from $7 to $6.

Benzinga Newsdesk